Macrogen, the South Korean public biotech company, the country's leading gene sequencing service provider, is developing a big data blockchain genomic platform together with the local technology company Bigster, according to a press release of 6 August.
The new partnership take advantage of blockchain technology to create a big data medical ecosystem that would allow both secure and private storage and the transfer of large amounts of sensitive genomic and personal information.
As the press release notes, advances in genomics are reshaping global landscape medicine, enabling personalized diagnosis, treatment and prevention. The big data doctors, which integrate genomic information, on the health and lifestyle of individuals, are both extremely sensitive and of exceptional value for the pharmaceutical and health industries.
Speaking to local news The Korea Herald, Macrogen CEO Yang Kap-seok commented,
"Despite its usefulness, data on genes have been difficult to move due to privacy protection issues and technological hurdles We hope that our impending blockchain-based platform will allow the health genet [ic] and large medical data to circulate freely. "
Macrogen and Bigster aim to develop the platform by June 2019 and decided to create a blockchain authorized that would limit access to specific institutions such as pharmaceutical companies, biotech companies, hospitals and research institutes.
As Cointelegraph reported this May, an American nebulae set a precedent for the use of the blockchain for the secure exchange of genomic data. Genomics Cooperation with Longenesis – this is a Hong Kong partnership with Insyl Medicine and the Bitfury Group.
In April, US health giant UnitedHealth Group announced that it would implement blockchain to keep its records updated in a more efficient, secure and accessible manner.